Abstract: The invention relates to an antiserum suitable for the determination of thioridazine in blood, blood plasma and urine, the use of the antiserum and a process of determining thioridazine in blood, blood plasma or urine with the aid of this specific antiserum.

Abstract: Tumor associated antigens are disclosed in both crude and pure form which are specific to human breast cancer. The antigens are designated BCA. Antisera, radiolabeled antigens and antisera, as well as methods for the detection of circulating BCA are also disclosed. Methods for the extraction of BCA also form part of the invention. A diagnostic kit for the detection of circulating BCA, especially one suitable for use in as radioimmunoassay is also disclosed.

Abstract: An antigen and a method for its preparation and use in detecting antibody to a selected diisocyanate is provided by reacting the monoisocyanate derivative of the diisocyanate or the diisocyanate with a protein, incubating the antigen on a paper disc with test serum in the presence of a buffer and anti-IgE-.sup.125 I and thereafter counting the disc with a scintillation spectrometer.

Abstract: A hapten is obtained by replacing the 3-hydroxy group of equilin with HO--CO--A--O-- wherein A is an alkylene of one to six carbon atoms. The hapten is conjugated with an immunological carrier to provide an immunogen, which in turn produces a specific antiserum to equilin. The antiserum is used in a radioimmunoassay for equilin.

Abstract: A hapten is obtained by replacing the 3-hydroxy group of 17 .alpha.-dihydroequilin with HO--CO--A--O-- wherein A is an alkylene of one to six carbon atoms. The hapten is conjugated with an immunological carrier to provide an immunogen, which in turn produces a specific antiserum to 17 .alpha.-dihydroequilin. The antiserum is used in a radioimmunoassay for 17 .alpha.-dihydroequilin.

Abstract: The present invention relates to a process for the production of vaccine, characterized by covalent attachment of a biologically toxic substance to a saccharide both to form a biologically toxic substance-saccharide conjugate and to detoxify said substance, followed by collection of the formed conjugate. According to the invention, various vaccine products having a high productivity of immunoglobulin G and M antibodies, but without productivity of immunoglobulin E antibody, are easily obtainable. In addition, the vaccine products, upon administration to animals, do not effect any allergic reaction and/or anaphylactic-shock due to the lack of the immunoglobulin E antibody production.